Search

Your search keyword '"U. Ganswindt"' showing total 247 results
Start Over Author "U. Ganswindt"
247 results on '"U. Ganswindt"'

2. Real-time intra-fraction motion management in breast cancer radiotherapy: analysis of 2028 treatment sessions

Author

D. Reitz, G. Carl, S. Schönecker, M. Pazos, P. Freislederer, M. Niyazi, U. Ganswindt, F. Alongi, M. Reiner, C. Belka, and S. Corradini

Subjects
Radiotherapy, Intrafraction motion, Breast cancer, Optical surface scanner, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Intra-fraction motion represents a crucial issue in the era of precise radiotherapy in several settings, including breast irradiation. To date, only few data exist on real-time measured intra-fraction motion in breast cancer patients. Continuous surface imaging using visible light offers the capability to monitor patient movements in three-dimensional space without any additional radiation exposure. The aim of the present study was to quantify the uncertainties of possible intra-fractional motion during breast radiotherapy. Material and methods One hundred and four consecutive patients that underwent postoperative radiotherapy following breast conserving surgery or mastectomy were prospectively evaluated during 2028 treatment sessions. During each treatment session the patients’ motion was continuously measured using the Catalyst™ optical surface scanner (C-RAD AB, Sweden) and compared to a reference scan acquired at the beginning of each session. The Catalyst system works through an optical surface imaging with light emitting diode (LED) light and reprojection captured by a charge coupled device (CCD) camera, which provide target position control during treatment delivery with a motion detection accuracy of 0.5 mm. For 3D surface reconstruction, the system uses a non-rigid body algorithm to calculate the distance between the surface and the isocentre and using the principle of optical triangulation. Three-dimensional deviations and relative position differences during the whole treatment fraction were calculated by the system and analyzed statistically. Results Overall, the maximum magnitude of the deviation vector showed a mean change of 1.93 mm ± 1.14 mm (standard deviation [SD]) (95%-confidence interval: [0.48–4.65] mm) and a median change of 1.63 mm during dose application (beam-on time only). Along the lateral and longitudinal axis changes were quite similar (0.18 mm ± 1.06 mm vs. 0.17 mm ± 1.32 mm), on the vertical axis the mean change was 0.68 mm ± 1.53 mm. The mean treatment session time was 154 ± 53 (SD) seconds and the mean beam-on time only was 55 ± 16 s. According to Friedman’s test differences in the distributions of the three possible directions (lateral, longitudinal and vertical) were significant (p

Published
2018
Full Text
View/download PDF

3. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial

Author

D. Zips, D.G. Bosetti, M. Pinkawa, Marcin Sumila, V. Budach, Davide G. Bosetti, P.M. Putora, G. Pesce, George N. Thalmann, Daniel M. Aebersold, Kaouthar Khanfir, Jürg Bernhard, Bülent Polat, F. Zimmermann, S. Gomez, Piet Ost, K. Berkovic, F. Behrensmeier, P. Wust, L. Plasswilm, J. Collon, P. Messer, S. Bodis, M. Baumann, Silvia Gomez, M. Sumila, V. Lewitzki, M. Sassowsky, H. Kranzbühler, Kathrin Zaugg, Peter Wust, D.M. Aebersold, P. Thum, M. Guckenberger, Matthias Guckenberger, Y. Najafi, S. Wuttke, C. Belka, D.R. Zwahlen, Guido Hildebrandt, Pirus Ghadjar, A. Papachristofilou, Philipp Gut, Corinne Schär, G.N. Thalmann, F. Vandaele, K. Beer, P. Ost, M. Stuschke, M. Flentje, A. Müller, C. Reuter, P. Ghadjar, C. Oehler, Christiane Reuter, Daniel R. Zwahlen, I. Tacacs, Arndt-Christian Müller, M. Brown, K. Khanfir, G. Hildebrandt, Ludwig Plasswilm, T. Hölscher, N.C. Azinwi, Tobias Hölscher, M.J. Eble, U. Ganswindt, Stefanie Hayoz, P. Gut, Alexandros Papachristofilou, B. Polat, and K. Zaugg

Subjects
Male, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Clinical endpoint, Humans, Medicine, Aged, Prostatectomy, Salvage Therapy, business.industry, Hazard ratio, Prostatic Neoplasms, Radiotherapy Dosage, Common Terminology Criteria for Adverse Events, Middle Aged, Prostate-Specific Antigen, medicine.disease, Radiation therapy, Clinical trial, 030220 oncology & carcinogenesis, Disease Progression, Quality of Life, Hormonal therapy, Neoplasm Recurrence, Local, business
Abstract

Background Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). Objective To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. Design, setting, and participants SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. Intervention Patients were randomly assigned to conventional-dose (64 Gy) or dose-intensified SRT (70 Gy) to the prostate bed without hormonal therapy. Outcome measurements and statistical analysis The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), acute and late toxicity (Common Terminology Criteria for Adverse Events v4.0), and quality of life (QoL). Results and limitations Between February 2011 and April 2014, 350 patients were randomly assigned to 64 Gy (n = 175) or 70 Gy (n = 175). Median prostate-specific antigen at randomization was 0.3 ng/ml. After median follow-up of 6.2 yr, the median FFBP was 8.2 yr in the 64 Gy arm and 7.6 in the 70 Gy arm (log-rank p = 0.4), with a hazard ratio of 1.14 (95% confidence interval 0.82–1.60). The 6-year FFBP rates were 62% and 61%, respectively. No significant differences in clinical PFS, time to hormonal treatment, or OS were observed. Late grade 2 and 3 genitourinary toxicity was observed in 35 (21%) and 13 (7.9%) patients in the 64 Gy arm, and 46 (26%) and seven (4%) in the 70 Gy arm, respectively (p = 0.8). Late grade 2 and 3 gastrointestinal toxicity was observed in 12 (7.3%) and seven patients (4.2%) in the 64 Gy arm, and 35 (20%) and four (2.3%) in the 70 Gy arm, respectively (p = 0.009). There were no significant differences in QoL. Conclusions Conventional-dose SRT to the prostate bed is sufficient in patients with early biochemical progression of prostate cancer after RP. Patient summary The optimal radiation therapy dose for patients who have increased tumor markers after surgery for prostate cancer is unclear. We found that administering a higher dose only increased the gastrointestinal side effects without providing any benefits to the patient. This clinical trial is registered on ClinicalTrials.gov as NCT01272050.

Published
2021
Full Text
View/download PDF

4. P-473 Low radiation affects follicle count in sheep ovaries

Author

R Saueressig, E Reiser, M Frank, S Tollinger, J Haybäck, U Ganswindt, and B Toth

Subjects
Reproductive Medicine, Rehabilitation, Obstetrics and Gynecology
Abstract

Study question What is the effect of low dose radiation on follicle count in sheep ovaries? Summary answer Even low dose radiation has a negative impact on the follicle count in sheep ovaries. What is known already Radiotherapy is a corner stone of state-of-the-art cancer treatment, especially in young cancer patients. Survival rates are constantly rising, resulting in long-term survivors with potential child wish. High doses of radiation lead to a permanent damage to the ovaries. Little is known about the damage after low dose radiation to the ovaries including both follicles and stroma. Study design, size, duration Prospective ongoing study, including n = 41 sheeps and 942 ovarian punches (Ø 3mm). So far, n = 12 sheep and n = 120 punches were analysed between April 2020 and January 2022. After finishing the experiments with sheep ovarian tissue, we will continue with a mouse model and human ovarian tissue. Participants/materials, setting, methods 942 cortex punches out of a total of n = 41 sheep were obtained and cryopreserved. After thawing the punches were radiated with a dose of 0.0, 0.5, or 9.0 Gy using a cesium 137 radionuklide source (GSR C1, GammaService Medical GmbH). The punches were fixed in formalin, embedded in paraffin, cut into serial sections of 3-5 µm and stained with Hematoxylin and Eosin for follicle counting as well as Caspase 3 and Ki67. Main results and the role of chance Follicle loss was already observed after low dose radiation (0.5 Gy). Mean follicle count after 0 Gy, 0.5 Gy, and 9 Gy were 7.5, 2.3 and 1.8, respectively. While after 0 Gy, no signs of degeneration were visible, after radiation with 9 Gy follicles showed strong signs of degeneration including disorganization of granulosa cells, pyknosis and stromal irregularities. Limitations, reasons for caution Limitations of our study include the pilot character and therefore small sample size. The presented data only display part of the overall project including also an in-vivo mouse model. Wider implications of the findings As even low dose radiation seems to damage ovarian follicles, further in-vivo studies are needed to confirm these results. Moreover, fertility preservation methods need to be offered consequently to young cancer patients receiving radiotherapy. Trial registration number 25

Published
2022
Full Text
View/download PDF

5. PO-0976 Adjuvant (chemo)radiotherapy in HNSCC patients: Outcome prediction with comorbidity risk scores

Author

Anna A. Friedl, Lars Schüttrumpf, R. Späth, Jochen Hess, Franziska Walter, S. Marschner, H. Zitzelsberger, Claus Belka, Cornelius Maihöfer, U. Ganswindt, Philipp Baumeister, and N. Kienlechner

Subjects
Oncology, medicine.medical_specialty, Chemo-radiotherapy, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Comorbidity, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, Outcome prediction, Adjuvant
Published
2021
Full Text
View/download PDF

7. OC-0638 Integrated radiogenomics analyses for outcome prognosis in patients with locally advanced HNSCC

Author

Goda Kalinauskaite, M. Krause, Daniel Zips, Claus Belka, Maja Guberina, Michael H. Baumann, J.C. Peecken, J. von der Grün, Fabian Lohaus, Esther G.C. Troost, A. Rabasco, Annett Linge, Panagiotis Balermpas, Alex Zwanenburg, Inge Tinhofer, S. Böcke, U. Ganswindt, Gustavo B. Baretton, Steffen Löck, Stephanie E. Combs, M. Grosser, and Nika Guberina

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Radiogenomics, medicine, Locally advanced, Radiology, Nuclear Medicine and imaging, In patient, Hematology, business, Outcome (game theory)
Published
2021
Full Text
View/download PDF

8. PD-0912 Outcome of PSMA-PET/CT based salvage radiotherapy for nodal recurrence after radical prostatectomy

Author

Paul Rogowski, Christian Trapp, R. von Bestenbostel, Claus Belka, Minglun Li, Nina-Sophie Schmidt-Hegemann, U. Ganswindt, Peter Bartenstein, and Christian G. Stief

Subjects
medicine.medical_specialty, Oncology, Prostatectomy, business.industry, Salvage radiotherapy, medicine.medical_treatment, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, Psma pet ct, NODAL, business
Published
2021
Full Text
View/download PDF

9. OC-0277 A 6-gene signature for loco-regional control prognosis in HNSCC patients treated by PORT-C

Author

Claus Belka, Michael H. Baumann, Jürgen Debus, David Mönnich, Volker Budach, Amir Abdollahi, Claus Rödel, Ali Sak, Inge Tinhofer, Annett Linge, S. Patil, Daniel Zips, Gustavo B. Baretton, Henning Schäfer, Steffen Löck, Steffi Pigorsch, U. Ganswindt, Panagiotis Balermpas, Volker Gudziol, A. Nowak, M. Stuschke, M. Grosser, M. Krause, Stephanie E. Combs, and A.L. Grosu

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Gene signature, business, Port (computer networking)
Published
2021
Full Text
View/download PDF

10. PD-0066: A 24-miRNA signature predicting HPV status in head and neck cancer

Author

Daniel Zips, P. Weber, Claus Rödel, Michael Henke, Martin Werner, M. Krause, Annett Linge, Jürgen Debus, Lars Schüttrumpf, Stephanie E. Combs, Philipp Baumeister, Kristian Unger, J. Heß, Henning Schäfer, Cornelius Maihoefer, H. Zitzelsberger, T. Heider, Axel Walch, U. Ganswindt, B. Michael, Martin Stuschke, C. Woischke, S. Marschner, Claus Belka, and Inge Tinhofer

Subjects
Oncology, Mirna signature, medicine.medical_specialty, business.industry, Internal medicine, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Hpv status
Published
2020
Full Text
View/download PDF

11. OC-0446: Senescence and associated cytokines are critical drivers of inherent radioresistance in HNSCC

Author

Verena Jendrossek, H. Zitzelsberger, S. Spörl, U. Ganswindt, A. Sieber, Claus Belka, L. Kinzel, Bertram Klinger, D. Klein, Kirsten Lauber, Jochen Hess, U. Schötz, N. Blüthgen, S. Shnayien, Kristian Unger, S. Unkel, and Cornelius Maihöfer

Subjects
Senescence, Oncology, Radioresistance, Cancer research, Radiology, Nuclear Medicine and imaging, Hematology, Biology
Published
2020
Full Text
View/download PDF

12. PO-1167: Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer

Author

Christian G. Stief, Chukwuka Eze, Peter Bartenstein, A. Kretschmer, Minglun Li, Paul Rogowski, Christian Schaefer, U. Ganswindt, Alexander Buchner, Claus Belka, Nina-Sophie Schmidt-Hegemann, and W.P. Fendler

Subjects
Oncology, medicine.medical_specialty, business.industry, Psma pet, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Recurrent prostate cancer, Hematology, NODAL, business
Published
2020
Full Text
View/download PDF

13. PV-0044 Mastectomy or breast-conserving therapy for early breast cancer: outcome comparison of 7565 cases

Author

Claus Belka, S. Schönecker, Filippo Alongi, D. Reitz, U. Ganswindt, Stefanie Corradini, Nadia Harbeck, Maximilian Niyazi, Michael Braun, and Montserrat Pazos

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Outcome (game theory), Mastectomy, Early breast cancer
Published
2019
Full Text
View/download PDF

14. EP-1979 Intrafraction stability of 8526 deep inspiration breath holds in left-sided breast cancer

Author

S. Schönecker, Claus Belka, P. Freislederer, Stefanie Corradini, Michael Reiner, Montserrat Pazos, U. Ganswindt, Maximilian Niyazi, and D. Reitz

Subjects
medicine.medical_specialty, Breast cancer, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, medicine.disease, business, Breath holds, Left sided
Published
2019
Full Text
View/download PDF

15. [Radiation therapy of locally advanced prostate cancer]

Author

N-S, Schmidt-Hegemann, M, Li, C, Eze, C, Belka, and U, Ganswindt

Subjects
Male, Manual Lymphatic Drainage, Risk Factors, Lymphatic Metastasis, Disease Progression, Humans, Prostatic Neoplasms, Androgen Antagonists, Neoplasm Invasiveness, Radiotherapy, Intensity-Modulated, Combined Modality Therapy, Neoplasm Staging, Radiotherapy, Image-Guided
Abstract

The risk classification for localized prostate cancer is based on the groups "low", "intermediate", and "high-risk" prostate cancer. Following this established risk group definition, locally advanced prostate cancer (cT3/4N0M0) has to be classified as "high-risk" prostate cancer. Radical prostatectomy or high-dose radiotherapy, which is combined with androgen deprivation, are the only curative standard treatments for locally advanced prostate cancer. Particularly adequate radiation doses, modern radiotherapy techniques like IMRT/IGRT, as well as long-term androgen suppression are essential for an optimal treatment outcome. In combination with definitive radiotherapy, androgen deprivation therapy should be started neoadjuvant/simultaneous to radiotherapy and is recommended to be continued after radiotherapy. Previous data suggest that 2‑year long-term androgen deprivation in this setting may not be inferior to 3‑year long-term androgen deprivation in high-risk patients. An additional radiation therapy of the lymphatic pathways in men with cN0 locally advanced/high-risk prostate cancer is still a matter of research. Ongoing trials may define selected subgroups with a suggested benefit at its best.

Published
2017

16. EP-2059: Real time optical surface IGRT: A mono-institutional prospective study of 110 patients

Author

U. Ganswindt, Stefanie Corradini, S. Schönecker, G. Carl, Claus Belka, Montserrat Pazos, Michael Reiner, P. Freislederer, D. Reitz, and Maximilian Niyazi

Subjects
medicine.medical_specialty, Oncology, business.industry, Optical surface, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Hematology, Prospective cohort study, business, Image-guided radiation therapy
Published
2018
Full Text
View/download PDF

18. EP-1977 Intrafraction motion in CNS radiotherapy with an open mask system using an optical surface imaging

Author

Stefanie Corradini, S. Schönecker, Claus Belka, P. Freislederer, U. Ganswindt, D. Reitz, Maximilian Niyazi, Michael Reiner, and Montserrat Pazos

Subjects
Radiation therapy, Materials science, Oncology, Intrafraction motion, medicine.medical_treatment, Optical surface, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Biomedical engineering
Published
2019
Full Text
View/download PDF

19. EP-1515 Substantial impact of 68Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer

Author

Paul Rogowski, Chukwuka Eze, Peter Bartenstein, Christian Schaefer, Minglun Li, Christian G. Stief, Claus Belka, U. Ganswindt, Nina-Sophie Schmidt-Hegemann, and Harun Ilhan

Subjects
PET-CT, Prostate cancer, Oncology, business.industry, 68ga psma, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Nuclear medicine, business, medicine.disease
Published
2019
Full Text
View/download PDF

20. Lokal fortgeschrittenes Prostatakarzinom und lokales Rezidiv

Author

Axel Heidenreich, U. Ganswindt, and D. Pfister

Subjects
Gynecology, medicine.medical_specialty, Oncology, business.industry, medicine, Hematology, business
Abstract

Hintergrund Die Therapie des lokal fortgeschrittenen Prostatakarzinoms wurde in der Vergangenheit kontrovers diskutiert. Haufig wurde ausschlieslich palliativ mit einer Hormontherapie behandelt.

Published
2013
Full Text
View/download PDF

21. [Not Available]

Author

Thomas G, Wendt, G, Gademann, C, Pambor, I, Grießbach, H, von Specht, T, Martin, D, Baltas, R, Kurek, S, Röddiger, U W, Tunn, N, Zamboglou, H T, Eich, S, Staar, A, Gossmann, K, Hansemann, R, Semrau, R, Skripnitchenko, V, Diehl, R-P, Müller, S, Sehlen, N, Willich, U, Rühl, P, Lukas, E, Dühmke, K, Engel, E, Tabbert, M, Bolck, S, Knaack, H, Annweiler, R, Krempien, H, Hoppe, W, Harms, S, Daeuber, O, Schorr, M, Treiber, J, Debus, M, Alber, F, Paulsen, M, Birkner, A, Bakai, C, Belka, W, Budach, K-H, Grosser, R, Kramer, B, Kober, M, Reinert, P, Schneider, A, Hertel, H, Feldmann, P, Csere, C, Hoinkis, G, Rothe, P, Zahn, H, Alheit, S X, Cavanaugh, P, Kupelian, C, Reddy, B, Pollock, M, Fuss, S, Roeddiger, T, Dannenberg, B, Rogge, D, Drechsler, T, Herrmann, W, Alberti, R, Schwarz, M, Graefen, A, Krüll, V, Rudat, H, Huland, C, Fehr, C, Baum, S, Glocker, F, Nüsslin, T, Heil, H, Lemnitzer, M, Knips, O, Baumgart, W, Thiem, K-H, Kloetzer, L, Hoffmann, B, Neu, B, Hültenschmidt, M-L, Sautter-Bihl, O, Micke, M H, Seegenschmiedt, D, Köppen, G, Klautke, R, Fietkau, J, Schultze, G, Schlichting, H, Koltze, B, Kimmig, M, Glatzel, D, Fröhlich, S, Bäsecke, A, Krauß, D, Strauß, K-J, Buth, R, Böhme, W, Oehler, D, Bottke, U, Keilholz, K, Heufelder, T, Wiegel, W, Hinkelbein, C, Rödel, T, Papadopoulos, M, Munnes, R, Wirtz, R, Sauer, F, Rödel, D, Lubgan, L, Distel, G G, Grabenbauer, A, Sak, G, Stüben, C, Pöttgen, S, Grehl, M, Stuschke, K, Müller, C, Pfaffendorf, A, Mayerhofer, F M, Köhn, J, Ring, D, van Beuningen, V, Meineke, S, Neubauer, U, Keller, M, Wittlinger, D, Riesenbeck, B, Greve, R, Exeler, M, Ibrahim, C, Liebscher, E, Severin, O, Ott, R, Pötter, J, Hammer, G, Hildebrandt, M W, Beckmann, V, Strnad, F, Fehlauer, S, Tribius, A, Bajrovic, U, Höller, D, Rades, A, Warszawski, R, Baumann, B, Madry-Gevecke, J H, Karstens, C, Grehn, F, Hensley, C, Berns, M, Wannenmacher, S, Semrau, T, Reimer, B, Gerber, P, Ketterer, E, Koepcke, G, Hänsgen, H G, Strauß, J, Dunst, J, Füller, S, Kalb, T, Wendt, H D, Weitmann, C, Waldhäusl, T-H, Knocke, U, Lamprecht, J, Classen, T W, Kaulich, B, Aydeniz, M, Bamberg, T, Wiezorek, N, Banz, H, Salz, M, Scheithauer, M, Schwedas, J, Lutterbach, S, Bartelt, H, Frommhold, J, Lambert, D, Hornung, S, Swiderski, M, Walke, A, Siefert, B, Pöllinger, K, Krimmel, M, Schaffer, O, Koelbl, K, Bratengeier, D, Vordermark, M, Flentje, B, Hero, F, Berthold, S E, Combs, S, Gutwein, D, Schulz-Ertner, M, van Kampen, C, Thilmann, M, Kocher, S, Kunze, S, Schild, K, Ikezaki, B, Müller, R, Sieber, C, Weiß, I, Wolf, F, Wenz, K-J, Weber, J, Schäfer, A, Engling, S, Laufs, M R, Veldwijk, D, Milanovic, K, Fleckenstein, W, Zeller, S, Fruehauf, C, Herskind, M, Weinmann, V, Jendrossek, C, Rübe, S, Appold, S, Kusche, T, Hölscher, K, Brüchner, P, Geyer, M, Baumann, R, Kumpf, F, Zimmermann, S, Schill, H, Geinitz, C, Nieder, B, Jeremic, M, Molls, S, Liesenfeld, H, Petrat, S, Hesselmann, U, Schäfer, F, Bruns, E, Horst, R, Wilkowski, G, Assmann, A, Nolte, J, Diebold, U, Löhrs, P, Fritz, K, Hans-Jürgen, W, Mühlnickel, P, Bach, B, Wahlers, H-J, Kraus, J, Wulf, U, Hädinger, K, Baier, T, Krieger, G, Müller, H, Hof, K, Herfarth, T, Brunner, S M, Hahn, F S, Schreiber, A K, Rustgi, W G, McKenna, E J, Bernhard, M, Guckenberger, K, Meyer, J, Willner, M, Schmidt, M, Kolb, M, Li, P, Gong, A, Abdollahi, T, Trinh, P E, Huber, H, Christiansen, B, Saile, K, Neubauer-Saile, S, Tippelt, M, Rave-Fränk, R M, Hermann, J, Dudas, C F, Hess, H, Schmidberger, G, Ramadori, N, Andratschke, R, Price, K-K, Ang, S, Schwarz, U, Kulka, M, Busch, L, Schlenger, J, Bohsung, I, Eichwurzel, G, Matnjani, D, Sandrock, M, Richter, R, Wurm, V, Budach, A, Feussner, J, Gellermann, A, Jordan, R, Scholz, U, Gneveckow, K, Maier-Hauff, R, Ullrich, P, Wust, R, Felix, N, Waldöfner, M, Seebass, H-J, Ochel, A, Dani, A, Varkonyi, M, Osvath, A, Szasz, P M, Messer, N M, Blumstein, H-W, Gottfried, E, Schneider, S N, Reske, E M, Röttinger, A-L, Grosu, M, Franz, S, Stärk, W, Weber, M, Heintz, F, Indenkämpen, T, Beyer, W, Lübcke, S, Levegrün, J, Hayen, N, Czech, B, Mbarek, R, Köster, H, Thurmann, M, Todorovic, A, Schuchert, T, Meinertz, T, Münzel, H, Grundtke, B, Hornig, T, Hehr, C, Dilcher, R C, Chan, G S, Mintz, J-I, Kotani, V M, Shah, D A, Canos, N J, Weissman, R, Waksman, R, Wolfram, B, Bürger, M, Schrappe, B, Timmermann, A, Lomax, G, Goitein, A, Schuck, A, Mattke, C, Int-Veen, I, Brecht, S, Bernhard, J, Treuner, E, Koscielniak, F, Heinze, M, Kuhlen, I, von Schorlemer, S, Ahrens, A, Hunold, S, Könemann, W, Winkelmann, H, Jürgens, J, Gerstein, B, Polivka, K-W, Sykora, M, Bremer, R, Thamm, C, Höpfner, H, Gumprecht, R, Jäger, M A, Leonardi, A M, Frank, A E, Trappe, C B, Lumenta, E, Östreicher, K, Pinsker, A, Müller, C, Fauser, W, Arnold, M, Henzel, M W, Groß, R, Engenhart-Cabillic, P, Schüller, S, Palkovic, J, Schröder, H, Wassmann, A, Block, R, Bauer, F-W, Keffel, B, Theophil, L, Wisser, M, Rogger, M, Niewald, V, van Lengen, K, Mathias, G, Welzel, M, Bohrer, S, Steinvorth, C, Schleußner, K, Leppert, B, Röhrig, B, Strauß, B, van Oorschot, N, Köhler, R, Anselm, A, Winzer, T, Schneider, U, Koch, K, Schönekaes, R, Mücke, J, Büntzel, K, Kisters, C, Scholz, M, Keller, C, Winkler, N, Prause, R, Busch, S, Roth, I, Haas, R, Willers, S, Schultze-Mosgau, J, Wiltfang, P, Kessler, F W, Neukam, B, Röper, N, Nüse, F, Auer, W, Melzner, M, Geiger, M, Lotter, T, Kuhnt, A C, Müller, N, Jirsak, C, Gernhardt, H-G, Schaller, B, Al-Nawas, M O, Klein, C, Ludwig, J, Körholz, K A, Grötz, K, Huppers, M, Kunkel, T, Olschewski, K, Bajor, B, Lang, E, Lang, U, Kraus-Tiefenbacher, R, Hofheinz, B, von Gerstenberg-Helldorf, F, Willeke, A, Hochhaus, M, Roebel, S, Oertel, S, Riedl, M, Buechler, T, Foitzik, K, Ludwig, E, Klar, A, Meyer, J, Meier Zu Eissen, D, Schwab, T, Meyer, S, Höcht, A, Siegmann, F, Sieker, S, Pigorsch, B, Milicic, L, Acimovic, S, Milisavljevic, G, Radosavljevic-Asic, N, Presselt, R P, Baum, D, Treutler, R, Bonnet, M, Schmücking, D, Sammour, T, Fink, J, Ficker, O, Pradier, K, Lederer, E, Weiss, A, Hille, S, Welz, S, Sepe, G, Friedel, W, Spengler, E, Susanne, O, Kölbl, W, Hoffmann, B, Wörmann, A, Günther, M, Becker-Schiebe, J, Güttler, C, Schul, M, Nitsche, M K, Körner, R, Oppenkowski, F, Guntrum, L, Malaimare, M, Raub, C, Schöfl, T, Averbeck, I, Hacker, H, Blank, C, Böhme, D, Imhoff, K, Eberlein, S, Weidauer, H D, Böttcher, L, Edler, M, Tatagiba, H, Molina, C, Ostertag, S, Milker-Zabel, A, Zabel, W, Schlegel, A, Hartmann, I, Wildfang, G, Kleinert, K, Hamm, W, Reuschel, R, Wehrmann, P, Kneschaurek, M W, Münter, A, Nikoghosyan, B, Didinger, S, Nill, B, Rhein, D, Küstner, U, Schalldach, D, Eßer, H, Göbel, H, Wördehoff, S, Pachmann, H, Hollenhorst, K, Dederer, C, Evers, J, Lamprecht, A, Dastbaz, B, Schick, J, Fleckenstein, P K, Plinkert, Chr, Rübe, T, Merz, B, Sommer, A, Mencl, V, Ghilescu, S, Astner, A, Martin, F, Momm, N J, Volegova-Neher, J, Schulte-Mönting, R, Guttenberger, A, Buchali, E, Blank, D, Sidow, W, Huhnt, T, Gorbatov, A, Heinecke, G, Beckmann, A-M, Bentia, H, Schmitz, U, Spahn, V, Heyl, P-J, Prott, R, Galalae, R, Schneider, C, Voith, A, Scheda, B, Hermann, L, Bauer, F, Melchert, N, Kröger, A, Grüneisen, F, Jänicke, A, Zander, I, Zuna, I, Schlöcker, K, Wagner, E, John, T, Dörk, G, Lochhas, M, Houf, D, Lorenz, K-H, Link, F-J, Prott, M, Thoma, R, Schauer, V, Heinemann, M, Romano, M, Reiner, A, Quanz, U, Oppitz, R, Bahrehmand, M, Tine, A, Naszaly, P, Patonay, Á, Mayer, K, Markert, S-K, Mai, F, Lohr, B, Dobler, M, Pinkawa, K, Fischedick, P, Treusacher, D, Cengiz, R, Mager, H, Borchers, G, Jakse, M J, Eble, B, Asadpour, B, Krenkel, R, Holy, Y, Kaplan, T, Block, H, Czempiel, U, Haverkamp, B, Prümer, T, Christian, P, Benkel, C, Weber, S, Gruber, P, Reimann, J, Blumberg, K, Krause, A-R, Fischedick, K, Kaube, K, Steckler, B, Henzel, N, Licht, T, Loch, A, Krystek, A, Lilienthal, H, Alfia, J, Claßen, P, Spillner, B, Knutzen, R, Souchon, I, Schulz, K, Grüschow, U, Küchenmeister, H, Vogel, D, Wolff, U, Ramm, J, Licner, F, Rudolf, J, Moog, C G, Rahl, S, Mose, H, Vorwerk, E, Weiß, A, Engert, I, Seufert, F, Schwab, J, Dahlke, T, Zabelina, W, Krüger, H, Kabisch, V, Platz, J, Wolf, B, Pfistner, B, Stieltjes, T, Wilhelm, M, Schmuecking, K, Junker, D, Treutier, C P, Schneider, J, Leonhardi, A, Niesen, K, Hoeffken, A, Schmidt, K-M, Mueller, I, Schmid, K, Lehmann, C G, Blumstein, R, Kreienberg, L, Freudenberg, H, Kühl, M, Stahl, B, Elo, P, Erichsen, H, Stattaus, T, Welzel, U, Mende, S, Heiland, B J, Salter, R, Schmid, D, Stratakis, R M, Huber, J, Haferanke, N, Zöller, M, Henke, J, Lorenzen, B, Grzyska, A, Kuhlmey, G, Adam, V, Hamelmann, T, Bölling, H, Job, J E, Panke, P, Feyer, S, Püttmann, B, Siekmeyer, H, Jung, B, Gagel, U, Militz, M, Piroth, A, Schmachtenberg, T, Hoelscher, C, Verfaillie, B, Kaminski, E, Lücke, H, Mörtel, W, Eyrich, M, Fritsch, J-C, Georgi, C, Plathow, H, Zieher, F, Kiessling, P, Peschke, H-U, Kauczor, J, Licher, O, Schneider, R, Henschler, C, Seidel, A, Kolkmeyer, T P, Nguyen, K, Janke, M, Michaelis, M, Bischof, C, Stoffregen, K, Lipson, K, Weber, V, Ehemann, D, Jürgen, P, Achanta, K, Thompson, J L, Martinez, T, Körschgen, R, Pakala, E, Pinnow, D, Hellinga, F, O'Tio, A, Katzer, A, Kaffer, A, Kuechler, S, Steinkirchner, N, Dettmar, N, Cordes, S, Frick, M, Kappler, H, Taubert, F, Bartel, H, Schmidt, M, Bache, S, Frühauf, T, Wenk, K, Litzenberger, M, Erren, F, van Valen, L, Liu, K, Yang, J, Palm, M, Püsken, M, Behe, T M, Behr, P, Marini, A, Johne, U, Claussen, T, Liehr, V, Steil, C, Moustakis, I, Griessbach, A, Oettel, C, Schaal, M, Reinhold, G, Strasssmann, I, Braun, P, Vacha, D, Richter, T, Osterham, P, Wolf, G, Guenther, M, Miemietz, E A, Lazaridis, B, Forthuber, M, Sure, J, Klein, H, Saleske, T, Riedel, P, Hirnle, G, Horstmann, H, Schoepgens, A, Van Eck, O, Bundschuh, A, Van Oosterhut, K, Xydis, K, Theodorou, C, Kappas, J, Zurheide, N, Fridtjof, U, Ganswindt, N, Weidner, M, Buchgeister, B, Weigel, S B, Müller, M, Glashörster, C, Weining, B, Hentschel, O A, Sauer, W, Kleen, J, Beck, D, Lehmann, S, Ley, C, Fink, M, Puderbach, W, Hosch, A, Schmähl, K, Jung, A, Stoßberg, E, Rolf, M, Damrau, D, Oetzel, U, Maurer, G, Maurer, K, Lang, J, Zumbe, D, Hahm, H, Fees, B, Robrandt, U, Melcher, M, Niemeyer, A, Mondry, V, Kanellopoulos-Niemeyer, H, Karle, D, Jacob-Heutmann, C, Born, W, Mohr, J, Kutzner, M, Thelen, M, Schiebe, U, Pinkert, L, Piasswilm, F, Pohl, S, Garbe, K, Wolf, Y, Nour, P, Barwig, D, Trog, C, Schäfer, M, Herbst, B, Dietl, M, Cartes, F, Schroeder, G, Sigingan-Tek, R, Feierabend, S, Theden, A, Schlieck, M, Gotthardt, U, Glowalla, S, Kremp, O, Hamid, N, Riefenstahl, B, Michaelis, G, Schaal, E, Liebermeister, U, Niewöhner-Desbordes, M, Kowalski, N, Franz, W, Stahl, C, Baumbach, J, Thale, W, Wagner, B, Justus, A L, Huston, R, Seaborn, P, Rai, S-W, Rha, G, Sakas, S, Wesarg, P, Zogal, B, Schwald, H, Seibert, R, Berndt-Skorka, G, Seifert, K, Schoenekaes, C, Bilecen, W, Ito, G, Matschuck, and D, Isik

Published
2016

22. EP-1323: Role of 68Ga-PSMA PET/CT in radiotherapy for prostate cancer: A single centre experience

Author

Nina-Sophie Hegemann, U. Ganswindt, Claus Belka, Christian G. Stief, Maximilian Niyazi, Alexander Buchner, Peter Bartenstein, and W.P. Fendler

Subjects
medicine.medical_specialty, PET-CT, business.industry, medicine.medical_treatment, 68ga psma, Hematology, medicine.disease, Radiation therapy, Prostate cancer, Single centre, Oncology, medicine, Radiology, Nuclear Medicine and imaging, Radiology, business
Published
2017
Full Text
View/download PDF

24. EP-1186: Real-time intrafraction motion in breast radiotherapy using an optical surface scanner

Author

Montserrat Pazos, S. Schönecker, Stefanie Corradini, P. Freislederer, Claus Belka, U. Ganswindt, D. Reitz, and Maximilian Niyazi

Subjects
Physics, medicine.medical_specialty, Scanner, business.industry, Breast radiotherapy, Hematology, Oncology, Intrafraction motion, Optical surface, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Nuclear medicine, business
Published
2017
Full Text
View/download PDF

25. EP-1222: Intrafraction motion in CNS and HNC radiotherapy: 399 fractions using an optical surface scanner

Author

Maximilian Niyazi, Claus Belka, S. Schönecker, Stefanie Corradini, Michael Reiner, G. Carl, Montserrat Pazos, P. Freislederer, U. Ganswindt, and D. Reitz

Subjects
Radiation therapy, Scanner, Materials science, Oncology, business.industry, medicine.medical_treatment, Intrafraction motion, Optical surface, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Nuclear medicine, business
Published
2018
Full Text
View/download PDF

26. EP-1551: Outcome after PSMA PET based RT in patients with biochemical recurrence or persistence after surgery

Author

Christian G. Stief, Claus Belka, W.P. Fendler, U. Ganswindt, Peter Bartenstein, and Nina-Sophie Schmidt-Hegemann

Subjects
Biochemical recurrence, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Psma pet, Medicine, Radiology, Nuclear Medicine and imaging, In patient, Hematology, business, Persistence (computer science)
Published
2018
Full Text
View/download PDF

27. Prostatakarzinom

Author

S.N. Reske, K. Miller, J. Walz, U. Ganswindt, S. Perner, J. Wierecky, I.A. Adamietz, and K. Czeloth

Subjects
Oncology, Hematology
Abstract

Das Prostatakarzinom ist das haufigste Karzinom des Mannes. Die Anzahl fruh entdeckter Tumoren stieg durch intensivierte Vorsorgeuntersuchungen, deren Effektivitat ist jedoch unzureichend. Die bildgebenden Verfahren bieten heute eine verbesserte Treffsicherheit, beantworten aber nicht alle Fragen. Der Einsatz von Biomarkern konnte kunftig die Diagnostik optimieren. Eine kurative Behandlung durch Operation und Bestrahlung ist bei lokal begrenzten Karzinomen moglich. Die Qualitat der Operation hangt v. a. von der Erfahrung des Operateurs, die Wirkung der Bestrahlung von der Prazision und der Dosis ab. Ein Fortschreiten der Erkrankung nach Primartherapie macht sich fruh durch einen PSA(prostataspezifisches Antigen)-Anstieg bemerkbar. Lokale Rezidive konnen anhangig von der Primartherapie radiotherapeutisch, chirurgisch oder medikamentos angegangen werden. Bei generalisierter Erkrankung kommen bestimmte chemotherapeutische Verfahren in Frage. Das klinische Management wird nach wie vor kontrovers diskutiert.

Published
2008
Full Text
View/download PDF

28. [Localized intermediate- to high-risk prostate cancer]

Author

S, Tritschler, U, Ganswindt, and C G, Stief

Subjects
Male, Prostatectomy, Evidence-Based Medicine, Treatment Outcome, Radiotherapy, Risk Factors, Germany, Practice Guidelines as Topic, Humans, Prostatic Neoplasms, Medical Oncology, Neoplasm Staging
Abstract

National and international guidelines recommend radical prostatectomy (RP) and radiotherapy (EBRT) as standard treatment for intermediate- and high-risk prostate cancer. Survival benefit of RP in prostate cancer has been proven in prospectively randomized trials. In contrast, the benefit of EBRT as well as the direct comparison of EBRT and RP have been investigated in several retrospective analyses, but are limited by typical problems associated with retrospective studies.Most of the studies comparing RP with EBRT favor RP with regard to overall survival and cancer-specific survival. Especially in young patients with high-grade prostate cancer, RP seems to be superior in comparison with EBRT. These patient are at high risk of a PSA recurrence and subsequently need an additional radiotherapy. Mortality and morbidity related to these both methods are low. Main complications of RP are urinary incontinence and erectile dysfunction. In contrast, rectal sequelae, erectile dysfunction, and irritative urinary symptoms are the main cause for postinterventional morbidity in patients after EBRT.

Published
2016

29. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node–based, intensity-modulated radiation therapy technique

Author

Frank Paulsen, Bettina Frey, S. Corvin, Markus Alber, Michael Bamberg, Claus Belka, Arnulf Stenzl, Roland Bares, Ilse Hundt, and U. Ganswindt

Subjects
Male, Cancer Research, medicine.medical_treatment, Urinary Bladder, Single-photon emission computed tomography, Pelvis, Prostate cancer, Colon, Sigmoid, Prostate, medicine, Humans, Radiology, Nuclear Medicine and imaging, Radiation treatment planning, Lymph node, Neoplasm Staging, Radiation, medicine.diagnostic_test, business.industry, Rectum, Prostatic Neoplasms, Radiotherapy Dosage, Prostate-Specific Antigen, Sentinel node, medicine.disease, Radiation therapy, medicine.anatomical_structure, Lymphatic system, Oncology, Lymphatic Metastasis, Lymph Nodes, Radiotherapy, Intensity-Modulated, Radiotherapy, Conformal, business, Nuclear medicine, Monte Carlo Method, Algorithms
Abstract

Purpose: Irradiation of adjuvant lymph nodes in high-risk prostate cancer was shown to be associated with improved rates of biochemical nonevidence of disease in the Radiation Therapy Oncology Group trial (RTOG 94-13). To account for the highly individual lymphatic drainage pattern we tested an intensity-modulated radiation therapy (IMRT) approach based on the determination of pelvic sentinel lymph nodes (SN). Methods and Materials: Patients with a risk of more than 15% lymph node involvement were included. For treatment planning, SN localizations were included into the pelvic clinical target volume. Dose prescriptions were 50.4 Gy to the adjuvant area and 70.0 Gy to the prostate. All treatment plans were generated using equivalent uniform dose (EUD)-based optimization algorithms and Monte Carlo dose calculations and compared with 3D conventional plans. Results: A total of 25 patients were treated and 142 SN were detectable (mean: n = 5.7; range, 0–13). Most SN were found in the external iliac (35%), the internal iliac (18.3%), and the iliac commune (11.3%) regions. Using a standard CT-based planning target volume, relevant SN would have been missed in 19 of 25 patients, mostly in the presacral/perirectal area (22 SN in 12 patients). The comparison of conventional 3D plans with the respective IMRT plans revealed a clear superiority of the IMRT plans. No gastrointestinal or genitourinary acute toxicity Grade 3 or 4 (RTOG criteria) occurred. Conclusions: Distributions of SN are highly variable. Data for SN derived from single photon emission computed tomography are easily integrated into an IMRT-based treatment strategy. By using SN data the probability of a geographic miss is reduced. The use of IMRT allows sparing of normal tissue irradiation.

Published
2007
Full Text
View/download PDF

31. Strahlentherapie beim Lokalrezidiv des Prostatakarzinoms

Author

C Belka and U Ganswindt

Subjects
Oncology, medicine.medical_specialty, Urinary continence, Prostatectomy, business.industry, Urology, medicine.medical_treatment, medicine.disease, Radiation therapy, Natural history, Prostate cancer, Meta-analysis, Internal medicine, medicine, Risk assessment, business, Adverse effect
Abstract

Approximately 25% of patients experience recurrent disease after radical prostatectomy. Most frequently, the only evidence of a relapse is a rising PSA level without clinical evidence. Without further treatment the natural history of PSA progression results in local recurrence or distant metastasis of prostate cancer. Since a proportion of these biochemical failures relate to a local recurrence, radiotherapy offers a potential curative approach. Up to now, no randomized studies are available. Therefore any decision can only be based on prospective observation studies or retrospective data. The data available indicate that optimal results can be obtained in patients with PSA levels below 1-2 ng/ml or even lower, a documented R1 resection, and a PSA doubling time>10 months. Doses of 64-66 Gy seem to be required for adequate control. Side effects are generally well acceptable and importantly no adverse effects on urinary continence have been documented. Taken together, radiotherapy is the only treatment option with curative potential in situations where a local failure is highly likely.

Published
2006
Full Text
View/download PDF

32. 70 Gy or more: which dose for which prostate cancer?

Author

Michael Bamberg, Aristotelis G. Anastasiadis, Frank Paulsen, U. Ganswindt, Claus Belka, and A. Stenzl

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, law.invention, Prostate cancer, Randomized controlled trial, law, Internal medicine, medicine, Humans, Survival rate, Clinical Trials as Topic, Prostatectomy, business.industry, Confounding, Prostatic Neoplasms, Radiotherapy Dosage, General Medicine, Prostate-Specific Antigen, medicine.disease, Surgery, Survival Rate, Radiation therapy, Prostate-specific antigen, Treatment Outcome, business, Adjuvant
Abstract

Introduction: Radical prostatectomy and radiotherapy are currently accepted treatment modalities for localized prostate cancer. Regarding radiotherapy, current evidence suggests that favorable treatment outcome critically depends on adequate radiation doses. However, the exact role of dose in relation to the individual risk profile is complex. In order to evaluate available data on radiation dose response relationships, in prostate cancer, a thorough and critical literature analysis was performed. Material and methods: Studies on dose response relationships from randomized trials, dose escalation trials, retrospective subgroup analyses and pooled data were identified by Pubmed and ISI web of sciences searches and were critically reviewed. Results and conclusion: All available data suggest a clear dose response relationship for radiotherapy for localized prostate cancer. In low risk cases, most studies suggest that doses of 70–72 Gy are adequate. Dose escalations up to 78–80 Gy seem to be beneficial for intermediate risk patients. Due to confounding variables, the dose response curves for high-risk patients are less steep. The integration of dose escalation into a more comprehensive treatment protocol is difficult, since trials on the relative impact of either hormonal ablation or inclusion of adjuvant nodal regions on dose escalation are missing

Published
2005
Full Text
View/download PDF

33. DEGRO 2004

Author

T Block, S. Röddiger, H. Fees, P. Feyer, T. Brunner, H. Karle, H. von Specht, M. Schwedas, A. Schmidt, H.-J. Ochel, N. Kröger, K. Müller, R. Waksman, M. Li, R. Sauer, S. Wesarg, A. Van Eck, D. Trog, R. Wilkowski, U. W. Tunn, K. Ikezaki, S. Könemann, L. Acimovic, Wolfgang Hinkelbein, Michael Bremer, E. Dühmke, J. Claßen, J.-I. Kotani, M. Püsken, J. Dudas, B. Pfistner, Christian Grehn, S. Ley, T. Martin, K. Maier-Hauff, A. Hartmann, Martin Weinmann, J. Kutzner, H. Vogel, I. Schmid, W. Lübcke, S. Roth, A. Krystek, Stefan Schultze-Mosgau, L. Freudenberg, J. Dahlke, P. K. Plinkert, Thomas Foitzik, M. Franz, C. Ludwig, O. Schorr, R. Wirtz, J. Klein, K. Krimmel, B. Weigel, A. K. Rustgi, J. Büntzel, W. Stahl, E. Pinnow, M. Graefen, S. Frühauf, K.-J. Buth, P. Reimann, E. A. Lazaridis, J. Lutterbach, C. Schleußner, R. Köster, Matthias Geiger, Beate Timmermann, D. A. Canos, Florian Auer, T. P. Nguyen, R. Anselm, T. M. Behr, Axel Müller, R. Bonnet, K. Leppert, Nicolaus Andratschke, Tilo Wiezorek, N. Prause, M. Tatagiba, M. Busch, N. Banz, M. van Kampen, P.-J. Prott, G. Schlichting, J. Körholz, M. Fritsch, B. Strauß, H. D. Böttcher, K. Schoenekaes, J. Schäfer, Renate Sieber, H. Jürgens, M. Schiebe, D. Milanovic, B. Al-Nawas, T. Beyer, B. Polivka, C. Fink, J. E. Panke, P. M. Messer, R. Kramer, C. F. Hess, D. Eßer, V. Steil, F. Bruns, Reinhard Thamm, R. Kumpf, M. Alber, U. Haverkamp, U. Mende, Christoph Thilmann, M. Bolck, M. W. Groß, Gunther Klautke, A. Zander, Sibylle Stärk, E. Tabbert, H. Taubert, M. Damrau, C. Weining, N. Franz, M. Puderbach, F. Melchert, L. Liu, W. Ito, S. Palkovic, B. Madry-Gevecke, T. Bölling, A. Kaffer, O. Micke, H. Schmidberger, M. Glashörster, A. Günther, S. Püttmann, A. Jordan, U. Claussen, Peter E. Huber, K. Lederer, S. Heiland, M. Niewald, H. Kühl, G. Gademann, Eugen Lang, B. Stieltjes, V. Ehemann, E. Horst, K. Heufelder, D. Fröhlich, S. Sepe, Roger E. Price, R. Bauer, E. Weiss, M. Reinhold, Moshe Schaffer, J.-C. Georgi, A. Dastbaz, Thomas Krieger, P. Hirnle, S. Garbe, D. Küstner, F. Pohl, N. Presselt, C. Voith, V. Meineke, P. Zogal, C. Herskind, S. Liesenfeld, F.-J. Prott, U. Kulka, Thomas Hendrik Knocke, T. Münzel, S. Kusche, Franz Rödel, Christian Ralf Gernhardt, C. Dilcher, Ute Küchenmeister, H. Alfia, N. Willich, D. Stratakis, G. Ramadori, R. Schmid, F. Zimmermann, L. Distel, K.-M. Mueller, V. Diehl, C. Höpfner, Frank Sieker, D. Cengiz, C. Plathow, E. Rolf, E. Schneider, W. Melzner, S.B. Schwarz, D. Sammour, D. Richter, I. Eichwurzel, H. Wassmann, A. L. Huston, B. Dietl, U. Melcher, F. Berthold, B. Kimmig, R. Mager, Richard Pötter, D. Drechsler, A. Lilienthal, A. Schmähl, M. Stuschke, A. Mencl, D. Schwab, H. Mörtel, O. Schneider, K.-W. Sykora, J. Willner, E. Lücke, N. Weidner, K. Hans-Jürgen, Sybille Gutwein, S. Kremp, R. Böhme, M. O. Klein, S. Nill, Hans-Günter Schaller, Matthias W. Beckmann, A. Feussner, M. Miemietz, A. Schmachtenberg, R. Seaborn, R.-P. Müller, Margret Rave-Fränk, A. Block, M. Gotthardt, I. Hacker, Á. Mayer, H.-W. Gottfried, G. Sakas, F. Nüsslin, M. Reinert, Markus Bohrer, H. Schmidt, A. Scheda, B. Dobler, T. Merz, K. Hansemann, K. A. Grötz, Grit Welzel, D. Isik, K. Wagner, P. Marini, C. Schäfer, M. Schrappe, T. Trinh, V. Rudat, M. Kowalski, T. Schneider, Daniela Schulz-Ertner, H. D. Weitmann, M. Henzel, I. Zuna, A. Nolte, Birgit Lang, K. Kian Ang, Thomas Wiegel, G. Seifert, A. Gossmann, D. van Beuningen, R. Wolfram, R. Hofheinz, K. Ludwig, T. Heil, M. Wittlinger, G. Lochhas, M. Houf, Robert Krempien, T. Averbeck, N. M. Blumstein, S. Astner, R. Willers, K.-J. Weber, J. Lorenzen, A. Krüll, U. Hädinger, C. Stoffregen, B. Pollock, S. Weidauer, U. Höller, M. Behe, B. Didinger, J. Gerstein, L. Bauer, S. Schill, M. Roebel, R. Schauer, J. Lamprecht, M. A. Leonardi, Otto A. Sauer, M. Molls, A. Varkonyi, Silke Tribius, U. Schäfer, V. Ghilescu, U. Keller, R. Galalae, E. Weiß, M. Buechler, W. Thiem, W. Winkelmann, S. N. Reske, T. Riedel, C. Int-Veen, Peter Geyer, A. Hunold, Barbara Röper, P. Peschke, M. Becker-Schiebe, I. Schulz, S. Bernhard, J. Fleckenstein, A. Hertel, H. Wördehoff, G. Müller, H. Grundtke, F. Rudolf, C. Böhme, Kurt Baier, R. Ullrich, S. Hesselmann, M. Raub, M. Schmidt, B. Hero, D. Sidow, C. Schöfl, U. Rühl, N. J. Volegova-Neher, C. Pöttgen, Stefan Glocker, Frank W. Hensley, Steven E. Schild, N. Dettmar, A. Quanz, R. Oppenkowski, A. Oettel, I. Seufert, U. Ganswindt, Volker Budach, H. Schoepgens, T. Fink, C. Ostertag, B. Milicic, R. C. Chan, F. Kiessling, J. Diebold, P. Rai, H.-U. Kauczor, H. Hoppe, P. Wolf, K. Litzenberger, M. Kappler, Peter Kneschaurek, Steffi Pigorsch, F. Momm, K. Kaube, Jörg Wiltfang, E. Koscielniak, J. Bohsung, J. Zumbe, K.-H. Grosser, N. Nüse, P. Erichsen, G. Kleinert, Chr. Rübe, P. Lukas, P. Spillner, C. Fehr, P. Benkel, O. Kölbl, N. Cordes, B. Hültenschmidt, Marc Bischof, N. J. Weissman, K. Yang, A. Engling, S. Milker-Zabel, Arndt-Christian Müller, B. Jeremic, D. Sandrock, Gabriele Hänsgen, C. Schul, Jörn Wulf, C. Fauser, M. Reiner, K. Dederer, M. Thelen, B. Grzyska, C. Evers, S. Daeuber, V. Platz, D. Riesenbeck, M. Erren, H. Zieher, W. Zeller, R. Bahrehmand, L. Wisser, K. Hoeffken, S. Kalb, M. Flentje, B. Greve, Claudia Waldhäusl, Fabian Fehlauer, Alessandra Siegmann, H. Czempiel, H. Stattaus, F. O’Tio, Vratislav Strnad, S. Frick, R. Kurek, E. Koepcke, R. Jäger, E. Severin, K. Krause, K. Pinsker, A.-R. Fischedick, P. Bach, S. Steinvorth, J. Blumberg, A. Stoßberg, Jörg Licher, S. X. Cavanaugh, R. Skripnitchenko, B. Mbarek, J. L. Martinez, V. van Lengen, Gabriele Beckmann, H. Saleske, E. Susanne, Christian Rübe, S. Mose, D. Rades, C. Scholz, P. Kupelian, T. W. Kaulich, M. Thoma, M. Stahl, A. Naszaly, M. R. Veldwijk, G. Radosavljevic-Asic, J. Schröder, Frank-Michael Köhn, L. Malaimare, Mathias Walke, K. Fischedick, M. Schmuecking, Gudrun Goitein, D. Hornung, T. Zabelina, N. Jirsak, K. Wolf, B. Schick, Mirko Nitsche, C. Pambor, K. Bajor, Isabell Braun, N. Czech, A. Sak, B. Hornig, Eric J. Bernhard, J. Meier zu Eissen, Michael Lotter, W. Hoffmann, L. Edler, Holger Hof, J. Lambert, M. Henke, C. Baum, B. Justus, W. Eyrich, I. Grießbach, T. Liehr, M. Wannenmacher, Peter Kessler, Klaus Eberlein, J. Dunst, A. E. Trappe, L. Hoffmann, S. Gruber, K. Mathias, S. Fruehauf, J. Hammer, J. H. Karstens, Erwin M. Röttinger, R. Schneider, G. Rothe, S. Milisavljevic, B. Pöllinger, H. Christiansen, A. Heinecke, Stefan Welz, B. Saile, W. Mühlnickel, M. Cartes, Rolf Kreienberg, M. Niemeyer, Claus Belka, T. Meyer, A. Nikoghosyan, Birgit Siekmeyer, K. Neubauer-Saile, Toralf Reimer, F. Bartel, M. Scheithauer, T. Osterham, Marc W. Münter, B. Theophil, N. Köhler, B. Krenkel, B. Hermann, M. Romano, T. Hölscher, T. Christian, M.-L. Sautter-Bihl, A. Bakai, K. Steckler, Franz Schwab, O. Bundschuh, S. Staar, G. Maurer, Johanna Gellermann, M. K. Körner, V. Hamelmann, T. Wenk, Jussi Moog, V. Heyl, S. Riedl, K. Lipson, T. Hehr, B. Röhrig, I. Schlöcker, I. Wildfang, H. Feldmann, D. Jürgen, A. Van Oosterhut, D. Vordermark, W. Schlegel, A. Kolkmeyer, R. Holy, N. Fridtjof, M. J. Eble, M. Pinkawa, S. Levegrün, P. Schneider, J. Debus, A. M. Frank, Andreas Engert, M. Bamberg, Reinhard Wurm, D. Treutler, M. Michaelis, Hans-Theodor Eich, I. Brecht, P. Gong, U. Keilholz, Martin Kocher, H. Salz, Oliver Koelbl, A. Schuchert, M. Osvath, H. Petrat, B. Asadpour, M. Birkner, B. Henzel, O. Hamid, Michael Baumann, G. Sigingan-Tek, B. Robrandt, B. Gerber, Ulf Lamprecht, J. Treuner, C. G. Rahl, G. Jakse, Roland Felix, N. Zöller, W. Krüger, F. Lohr, S.-K. Mai, C. Reddy, V. M. Shah, T. Olschewski, Wolfgang Harms, Martin Fuss, K. Markert, A. Kuechler, F. S. Schreiber, K.-H. Kloetzer, Jan Palm, F. Jänicke, R. Scholz, Y. Nour, W. Mohr, R. Exeler, D. Strauß, U. Oppitz, A. Kuhlmey, A. Schuck, K. Lang, A. Hille, A. Dani, R. Wehrmann, A. Hochhaus, L. Piasswilm, C. Winkler, B. van Oorschot, F.-W. Keffel, K. Jung, H. Gumprecht, R. Henschler, S. Swiderski, N. Waldöfner, Thilo Dörk, J. Thale, I. Griessbach, Dirk Bottke, F. Heinze, S. Roeddiger, S. Laufs, Detlef Imhoff, H. Annweiler, C. Verfaillie, M. Knips, R. Baumann, P. Barwig, P. Ketterer, B. Hentschel, Christiane Berns, M. Keller, B. Forthuber, G. S. Mintz, Martina Treiber, C. Moustakis, W. Huhnt, W. Oehler, U. Maurer, Juergen Wolf, H. Alheit, B. Kober, Guido Hildebrandt, R. Guttenberger, H. Vorwerk, Peter Vacha, N. Zamboglou, H. Job, O. Pradier, R. M. Huber, C. Pfaffendorf, Jürgen Füller, K. Engel, J. Zurheide, Artur Mayerhofer, D. Hahm, C. Nieder, U. Löhrs, J. Leonhardi, H. Thurmann, F. Willeke, D. Köppen, T. Dannenberg, G. Matschuck, E. Blank, B. von Gerstenberg-Helldorf, C. Seidel, H. Borchers, H. Lemnitzer, Rainer Souchon, A. Siefert, G. Strasssmann, K. Huppers, C. Schaal, H. Frommhold, W. Hosch, S. Theden, T. Wilhelm, U. Spahn, S. Höcht, Robert Semrau, J. Schultze, I. von Schorlemer, N. Riefenstahl, W. Reuschel, A.-M. Bentia, U. Glowalla, U. Schalldach, Verena Jendrossek, Amira Bajrovic, M. Schmücking, S.-W. Rha, B. Neu, M. Kuhlen, Markus Buchgeister, D. Treutier, T. Körschgen, Susanne Oertel, A. Schlieck, F. Schroeder, F. Paulsen, B. Knutzen, K. Kisters, F. van Valen, S. Tippelt, R. Pakala, J. Beck, Anca-Ligia Grosu, J. Hayen, Klaus Bratengeier, U. Militz, Raymonde Busch, S. Pachmann, M. Bache, M. Seebass, C. G. Blumstein, D. Lorenz, A. Johne, B. Kaminski, S. Neubauer, P. Zahn, Wolfgang A. Weber, M. Tine, M. Herbst, K. Junker, Thomas G. Wendt, Johannes Classen, C. Bilecen, S. Appold, P. Fritz, H. Koltze, M. Piroth, H. Molina, A. Zabel, C. B. Lumenta, B. Müller, Susanne Sehlen, Y. Kaplan, K. Brüchner, J. Güttler, S. Kunze, B. Schwald, C. Born, Rudolf Schwarz, E. Östreicher, G. Guenther, G. Friedel, Amir Abdollahi, Kathleen Grüschow, M. Glatzel, M. Richter, H. G. Strauß, Thomas Kuhnt, Klaus Herfarth, M. Guckenberger, K. Theodorou, A. Szasz, H. Schmitz, U. Kraus-Tiefenbacher, W. Budach, A. Winzer, Sabine Semrau, A. Mondry, M. Munnes, Peter Wust, W. Alberti, C. P. Schneider, G. Adam, S. Grehl, Stephen M. Hahn, B. Aydeniz, B. J. Salter, D. Wolff, P. Csere, P. Patonay, Robert Michael Hermann, S. Bäsecke, U. Koch, L. Schlenger, M. Rogger, T. Meinertz, R. Berndt-Skorka, V. Heinemann, Dieter Oetzel, Friedrich Wilhelm Neukam, H. Seibert, B. Rogge, C. Kappas, Anthony Lomax, Hans Geinitz, B. Sommer, K. Lehmann, A. Martin, I. Wolf, Rita Engenhart-Cabillic, C. Baumbach, G. G. Grabenbauer, Johannes Ring, K. Thompson, T. Wendt, S. Ahrens, C. Liebscher, G. Schaal, S. Steinkirchner, G. Horstmann, B. Wahlers, Ernst Klar, T. Loch, G. Assmann, W. G. McKenna, A. Mattke, S. Knaack, U. Ramm, P. Schüller, T. Gorbatov, D. Hellinga, W. Wagner, Hilbert Blank, W. Kleen, K. Janke, T. Welzel, W. Arnold, K. Fleckenstein, U. Gneveckow, K. Xydis, I. Haas, G. Stüben, B. Gagel, B. Wörmann, M. Ibrahim, A. Warszawski, A. Niesen, B. Elo, H. Kabisch, K. Meyer, Claus Rödel, H. Göbel, C. Weiß, U. Pinkert, N. Licht, Rainer Fietkau, Th. Herrmann, S. Bartelt, D. Lehmann, O. Baumgart, D. Jacob-Heutmann, P. Treusacher, H. Hollenhorst, J. Ficker, D. Baltas, C. Weber, B. Prümer, V. Kanellopoulos-Niemeyer, H. Jung, T. Hoelscher, Thomas Papadopoulos, M. Sure, O. Ott, H. Huland, Cordelia Hoinkis, F. Wenz, B. Bürger, H.-J. Kraus, Klaus-Josef Weber, M. Todorovic, F. Indenkämpen, J. Licner, Astrid Katzer, D. Lubgan, K.-H. Link, E. Liebermeister, B. Michaelis, G. Matnjani, M. Heintz, F. Guntrum, A. Grüneisen, A. Krauß, J. Schulte-Mönting, P. Achanta, Stephanie E. Combs, E. John, R. P. Baum, J. Haferanke, R. Feierabend, M. H. Seegenschmiedt, B. Rhein, M. Kolb, W. Spengler, A. Meyer, U. Niewöhner-Desbordes, A. Buchali, R. Mücke, K. Hamm, S. B. Müller, M. Kunkel, and K. Schönekaes

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Oncology, business.industry, MEDLINE, Medicine, Radiology, Nuclear Medicine and imaging, business, 030218 nuclear medicine & medical imaging
Published
2004
Full Text
View/download PDF

35. PD-0528: An update on re-irradiation and bevacizumab in recurrent highgrade glioma

Author

Maximilian Niyazi, Jörg C. Tonn, S.B. Schwarz, U. Ganswindt, Friedrich W. Kreth, Claus Belka, Maya Flieger, C. la Fougère, Jennifer Linn, and Lorenz Ertl

Subjects
Re-Irradiation, Bevacizumab, Oncology, business.industry, Radiology Nuclear Medicine and imaging, Glioma, medicine, Cancer research, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, medicine.drug
Published
2013
Full Text
View/download PDF

36. PO-0740: Nodal clearance rate and efficacy of individualised SN-based pelvic IMRT for prostate cancer

Author

Markus Alber, Frank Paulsen, Franziska Eckert, Roland Bares, P. Martus, Daniela Schilling, Claus Belka, Arnulf Stenzl, Daniel Zips, D. Weckermann, U. Ganswindt, and A. Müller

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Prostate cancer, Radiology Nuclear Medicine and imaging, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, NODAL, Clearance rate
Published
2016
Full Text
View/download PDF

37. EP-1804: A comparative analyse of prostate positioning guided by transperineal 3D ultrasound and cone beam CT

Author

Farkhad Manapov, U. Ganswindt, Claus Belka, Nina-Sophie Hegemann, Hendrik Ballhausen, Michael Reiner, S. Tritschler, and Minglun Li

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Hematology, medicine.anatomical_structure, Oncology, Radiology Nuclear Medicine and imaging, Prostate, Medicine, Radiology, Nuclear Medicine and imaging, 3D ultrasound, Radiology, business, Cone beam ct
Published
2016
Full Text
View/download PDF

38. Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax

Author

Wilfried Budach, René Handrick, Claus Belka, H. Faltin, Peter T. Daniel, U. Ganswindt, Verena Jendrossek, and Barbara Goecke

Subjects
musculoskeletal diseases, Oncology, Male, medicine.medical_specialty, Apoptosis, Prostate cancer, Internal medicine, Cell Line, Tumor, medicine, Cytotoxic T cell, Humans, heterocyclic compounds, Radiology, Nuclear Medicine and imaging, Cyclooxygenase Inhibitors, Clonogenic assay, Intraepithelial neoplasia, Sulfonamides, business.industry, Cell growth, Prostatic Neoplasms, Hematology, medicine.disease, Cell culture, Celecoxib, Pyrazoles, business, medicine.drug
Abstract

The cyclooxygenase-2-inhibitor celecoxib has been shown to inhibit cell growth and to reduce prostatic intraepithelial neoplasia in mice. The drug was suggested to increase efficacy of ionizing radiation. However, extent and mechanisms of the suggested benefit of celecoxib on the radiation response are still unclear. The aim of the present study was to analyze cytotoxic efficacy of celecoxib in combination with irradiation on human prostate cancer cell lines and to define the importance of pro-apoptotic Bax in this process.Induction of apoptosis and global and clonogenic cell survival upon irradation- (2-10Gy), celecoxib- (10-75microM) or combined treatment were evaluated in prostate cancer cells by fluorescence microscopy, WST-1 assay and standard colony formation assays.Celecoxib25microM caused morphological changes and growth inhibition without substantial apoptosis or radiosensitization in terms of decreased clonogenic cell survival. In contrast, celecoxib 25microM increased radiation-induced cell death and clonogenic kill. While radiation-induced clonogenic death was increased in the presence of Bax, effects of celecoxib or combined treatment were Bax independent.Our findings reveal Bax-independent beneficial effects of celecoxib on radiation-induced apoptosis and eradication of clonogenic prostate cancer cells in vitro providing a rationale for clinical evaluation of high-dose celecoxib in combination with irradiation in prostate cancer patients.

Published
2008

39. [Recurrence of prostate cancer--value of salvage radiotherapy]

Author

C, Belka and U, Ganswindt

Subjects
Male, Prostatectomy, Salvage Therapy, Treatment Outcome, Radiotherapy, Risk Factors, Prevalence, Humans, Prostatic Neoplasms, Neoplasm Recurrence, Local, Prostate-Specific Antigen, Risk Assessment
Abstract

Approximately 25% of patients experience recurrent disease after radical prostatectomy. Most frequently, the only evidence of a relapse is a rising PSA level without clinical evidence. Without further treatment the natural history of PSA progression results in local recurrence or distant metastasis of prostate cancer. Since a proportion of these biochemical failures relate to a local recurrence, radiotherapy offers a potential curative approach. Up to now, no randomized studies are available. Therefore any decision can only be based on prospective observation studies or retrospective data. The data available indicate that optimal results can be obtained in patients with PSA levels below 1-2 ng/ml or even lower, a documented R1 resection, and a PSA doubling time10 months. Doses of 64-66 Gy seem to be required for adequate control. Side effects are generally well acceptable and importantly no adverse effects on urinary continence have been documented. Taken together, radiotherapy is the only treatment option with curative potential in situations where a local failure is highly likely.

Published
2006

40. External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis

Author

U. Ganswindt, Thomas Hehr, Michael Bamberg, and Bernhard Berger

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Synovectomy, Synovitis, Pigmented Villonodular, Asymptomatic, Giant-cell tumor of the tendon sheath, Synovitis, medicine, Humans, Radiology, Nuclear Medicine and imaging, External beam radiotherapy, Radical surgery, Aged, Retrospective Studies, Radiation, business.industry, Radiotherapy Dosage, Middle Aged, medicine.disease, Surgery, Radiation therapy, Oncology, Pigmented villonodular synovitis, Female, Radiology, medicine.symptom, business, Follow-Up Studies
Abstract

Purpose: Diffuse pigmented villonodular synovitis is a rare proliferative disorder of synovial membranes with invasive and expansive growth patterns. Radical synovectomy is regarded as the treatment of choice. However, because of the high recurrence rates, additive treatment might be useful. Radiotherapy (RT) has been evaluated with positive results, but the optimal treatment schedules are vague. We have reviewed our experience with postoperative RT in cases of suspected or proven residual disease. Methods and Materials: Between December 1996 and January 2006, 7 diffuse pigmented villonodular synovitis patients underwent RT at our institution. The most common location was the knee joint (5 patients). All patients underwent radical surgery and were treated subsequently with 6-MV photon RT. The total doses applied were 30–50 Gy, depending on the resection status and estimated risk of relapse. For analysis, we retrospectively reviewed all patients in April 2006. Results: The mean follow-up time was 29 months (range, 3–112 months). RT had no acute adverse effects. At the assessment, no evidence was found of recurrent or persisting disease in any patient. Of the 7 patients, 6 reported asymptomatic limb function and excellent quality of life; 1 patient had persistent restriction of joint movement after repeated surgery. No radiotherapeutic late effects were seen. Conclusion: The results of our series have confirmed the efficacy and safety of postoperative RT for diffuse pigmented villonodular synovitis. Hence, this treatment should be considered for patients with suspected or proven residual disease.

Published
2006

41. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer – a phase I study

Author

Michael Bamberg, Wilfried Budach, Verena Jendrossek, Claus Belka, U. Ganswindt, and Gerd Becker

Subjects
Male, Risk, lcsh:Medical physics. Medical radiology. Nuclear medicine, Oncology, medicine.medical_specialty, Side effect, lcsh:R895-920, medicine.medical_treatment, Urology, lcsh:RC254-282, Prostate cancer, Prostate, Internal medicine, medicine, Humans, Cyclooxygenase Inhibitors, Radiology, Nuclear Medicine and imaging, Aged, Neoplasm Staging, Sulfonamides, Radiotherapy, business.industry, Research, Prostatic Neoplasms, Cancer, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Combined Modality Therapy, Acute toxicity, Radiation therapy, Treatment Outcome, medicine.anatomical_structure, Celecoxib, Toxicity, Pyrazoles, Safety, business, medicine.drug
Abstract

Background Current approaches for the improvement of bNED for prostate cancer patients treated with radiotherapy mainly focus on dose escalation. However molecularly targeted approaches may also turn out to be of value. In this regard cyclooxygenase (COX)-2 inhibitors have been shown to exert some anti-tumour activities in human prostate cancer in vivo and in vitro. Although in vitro data indicated that the combination of COX-2 inhibition and radiation was not associated with an increased toxicity, we performed a phase I trial using high dose celecoxib together with percutaneous radiation therapy. Methods In order to rule out any increases of more than 20% incidence for a given side effect level 22 patients were included in the trial. Celecoxib was given 400 mg twice daily with onset of the radiation treatment. Risk adapted radiation doses were between 70 and 74 Gy standard fractionation. RTOG based gastrointestinal (GI) and genitourinary (GU) acute toxicity scoring was performed weekly during radiation therapy, at six weeks after therapy and three month after completing radiation treatment. Results Generally no major increase in the level and incidence of side effects potentially caused by the combined treatment was observed. In two cases a generalised skin rash occurred which immediately resolved upon discontinuation of the drug. No grade 3 and 4 toxicity was seen. Maximal GI toxicity grade 1 and 2 was observed in 85% and 10%, respectively. In terms of GU toxicity 80 % of the patients experienced a grade 1 toxicity and 10 % had grade 2 symptoms. Conclusion The combination of irradiation to the prostate with concurrent high dose celecoxib was not associated with an increased level of side effects.

Published
2006
Full Text
View/download PDF

43. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition

Author

Aristotelis G. Anastasiadis, Frank Paulsen, U. Ganswindt, Roland Bares, Wilfried Budach, Claus Belka, S. Corvin, Ilse Hundt, Michael Bamberg, Stefan Glocker, M Birkner, Markus Alber, Arnulf Stenzl, and Kai Eichhorn

Subjects
Oncology, Male, Risk, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Sentinel lymph node, Rectum, lcsh:RC254-282, Prostate cancer, Prostate, Internal medicine, Spect imaging, Genetics, medicine, Humans, Radiometry, Aged, Tomography, Emission-Computed, Single-Photon, business.industry, Radiotherapy Planning, Computer-Assisted, Prostatic Neoplasms, Radiotherapy Dosage, Sentinel node, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Radiation therapy, medicine.anatomical_structure, Concomitant, Lymphatic Metastasis, Radiology, Lymph Nodes, Radiotherapy, Intensity-Modulated, Radiotherapy, Conformal, business, Tomography, X-Ray Computed, Research Article
Abstract

Background The RTOG 94-13 trial has provided evidence that patients with high risk prostate cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target volume definition for the pelvic lymph nodes is problematic. To overcome this limitation, we tested the feasibility of an intensity modulated radiation therapy (IMRT) protocol, taking under consideration the individual pelvic sentinel node drainage pattern by SPECT functional imaging. Methods Patients with high risk prostate cancer were included. Sentinel nodes (SN) were localised 1.5–3 hours after injection of 250 MBq 99mTc-Nanocoll using a double-headed gamma camera with an integrated X-Ray device. All sentinel node localisations were included into the pelvic clinical target volume (CTV). Dose prescriptions were 50.4 Gy (5 × 1.8 Gy / week) to the pelvis and 70.0 Gy (5 × 2.0 Gy / week) to the prostate including the base of seminal vesicles or whole seminal vesicles. Patients were treated with IMRT. Furthermore a theoretical comparison between IMRT and a three-dimensional conformal technique was performed. Results Since 08/2003 6 patients were treated with this protocol. All patients had detectable sentinel lymph nodes (total 29). 4 of 6 patients showed sentinel node localisations (total 10), that would not have been treated adequately with CT-based planning ('geographical miss') only. The most common localisation for a probable geographical miss was the perirectal area. The comparison between dose-volume-histograms of IMRT- and conventional CT-planning demonstrated clear superiority of IMRT when all sentinel lymph nodes were included. IMRT allowed a significantly better sparing of normal tissue and reduced volumes of small bowel, large bowel and rectum irradiated with critical doses. No gastrointestinal or genitourinary acute toxicity Grade 3 or 4 (RTOG) occurred. Conclusion IMRT based on sentinel lymph node identification is feasible and reduces the probability of a geographical miss. Furthermore, IMRT allows a pronounced sparing of normal tissue irradiation. Thus, the chosen approach will help to increase the curative potential of radiotherapy in high risk prostate cancer patients.

Published
2005

44. EP-1538 IMPACT OF MLC PROPERTIES AND IMRT TECHNIQUES TO THE PLAN QUALITY – PROSTATE WITH AND WITHOUT PELVIC LYMPH NODES

Author

H. Weingandt, Markus Alber, Michael Reiner, Claus Belka, S. Kantz, U. Ganswindt, and Matthias Söhn

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, Hematology, Plan (drawing), Pelvic lymph nodes, medicine.anatomical_structure, Oncology, Prostate, Medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Quality (business), business, media_common
Published
2012
Full Text
View/download PDF

45. 419 Individual risk for biochemical recurrence in localized prostate cancer with positive surgical margins: A multicentre study

Author

K-D. Sievert, Bernd Wullich, Alexander Karl, Ruth Knüchel-Clarke, Armin Pycha, F. Vom Dorp, Fabian Eder, Christiane Tympner, Evi Comploj, Michael Rogenhofer, Daniel Porres-Knoblauch, Claus Belka, T. Kirchner, Dirk Pehrke, Falko Fend, Alexander Buchner, A. Hartmann, W.F. Wieland, A. Stenzl, U. Ganswindt, Ferdinand Hofstädter, C.G. Stief, Alexander Haese, Roman Ganzer, Herbert Rübben, Kurt Werner Schmid, M. Graefen, Guido Sauter, E. Hanspeter, David Schilling, Birgit Hangarter, Axel Heidenreich, and M. Scharpf

Subjects
Oncology, Biochemical recurrence, medicine.medical_specialty, Prostate cancer, business.industry, Urology, Internal medicine, medicine, Positive Surgical Margin, medicine.disease, business, Individual risk
Published
2014
Full Text
View/download PDF

47. 126 Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node optimized target volume definition

Author

Michael Bamberg, S. Corvin, U. Ganswindt, I. Hundt, Claus Belka, Markus Alber, S. Glockerl, and Frank Paulsen

Subjects
Oncology, medicine.medical_specialty, business.industry, Planning target volume, Hematology, Sentinel node, medicine.disease, Prostate cancer, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Intensity modulated radiotherapy, business
Published
2006
Full Text
View/download PDF

49. EP-1330: Individual risk for biochemical recurrence in T2/T3a R1 prostate cancer - a multicenter study

Author

Alexander Haese, Armin Pycha, R. Knuechel-Clarke, Jochen Hess, Roman Ganzer, Arndt Hartmann, U. Ganswindt, Claus Belka, Alexander Karl, and David Schilling

Subjects
Biochemical recurrence, Oncology, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Individual risk, Prostate cancer, Multicenter study, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2014
Full Text
View/download PDF

50. PO-0736: Pattern of failure after sentinel node based individualization of pelvic IMRT for high risk prostate cancer

Author

David Schilling, Franziska Eckert, Claus Belka, Frank Paulsen, Arnulf Stenzl, Roland Bares, U. Ganswindt, Arndt-Christian Müller, Markus Alber, and Michael Bamberg

Subjects
Oncology, Patterns of failure, medicine.medical_specialty, Prostate cancer, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Sentinel node, business, medicine.disease
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results